SHINE Technologies has raised $240M to expand its nuclear medicine operations, including large-scale production of Lutetium-177 used in targeted cancer therapies, following its recent acquisition of Lantheus’ SPECT business...
SHINE Technologies signed a Letter of Intent with Swedish biotech Affibody AB to supply non-carrier-added Lutetium-177 for clinical development of its radioligand therapy pipeline, including Phase 1 candidate ABY-271, with potential commercial supply to be explored if the program advances...
Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, Medical Isotopes, Neutron services, NEWS, Nuclear R&D, Portfolio Venture, Private companies
SHINE Technologies, a Nucleation portfolio venture and next-generation fusion company, today announced a strategic partnership with Sumitomo Corporation of Americas (SCOA), a leading global trading and investment company. The partnership, formalized through a Memorandum of Understanding (MOU), will explore and develop pathways for SCOA to promote and distribute SHINE's innovative products and services throughout Japan and other Asian markets.
Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, International Collaboration, INTERNATIONAL NEWS, Medical Isotopes, Neutron services, NEWS, Nuclear waste, Portfolio Venture, Private companies
Sign up to receive Nucleation Insights
For New Investors
For Donors & Advocates
For Current Investors
(Note: Must be logged in at AngelList)
Nucleation Direct Messages
Nucleation (Fund I) Posts
Your Portfolio Dashboard
Your Funding Page
How to Contact Us
